Literature DB >> 7673491

Results of evaluation of 203 patients for photosensitivity in a 7.3-year period.

J Fotiades1, N A Soter, H W Lim.   

Abstract

BACKGROUND: Although photosensitivity disorders have been well described, their incidence in a referral institution had not been studied.
OBJECTIVE: The purpose of this study was to evaluate the incidence of photosensitivity disorders, including photocontact dermatitis, in an academic medical center.
METHODS: The results of the assessment of 203 consecutive patients, all of whom had phototests, referred for the evaluation of photosensitivity disorders during a 7.3-year period were reviewed.
RESULTS: The mean age was 50 years, and 63% of the patients were women. The most frequent diagnoses were polymorphous light eruption (26% of the total patient population), chronic actinic dermatitis (17%), photoallergic contact dermatitis (8%), systemic phototoxicity to therapeutic agents (7%), and solar urticaria (4%). Positive photopatch reactions, patch test reactions, or both were observed in 40 (29%) of the 138 tested patients. The frequencies of the positive photopatch test reactions were sunscreens (57%), fragrances (18%), and antimicrobial agents (13%). Of the positive patch test responses, fragrances elicited 47% of the total positive reactions, followed by sunscreens (39%) and antimicrobial agents (7%).
CONCLUSION: Polymorphous light eruption, chronic actinic dermatitis, and photoallergic contact dermatitis were the most frequently made diagnoses. Sunscreens, fragrances, and antimicrobial agents were the most common clinically relevant photoallergens and allergens.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7673491     DOI: 10.1016/0190-9622(95)91277-0

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  1 in total

Review 1.  Chronic actinic dermatitis in the elderly: recognition and treatment.

Authors:  Robert S Dawe
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.